#United States #New York #Venture Capital #Luma Group #LumaBio Fund

Luma Group Closes $410 Million for LumaBio Fund I

Luma Group, a prominent investment firm located in New York, has announced a significant milestone with the closure of its inaugural venture capital fund, LumaBio Fund I. The fund has successfully raised a total of $410 million, marking a crucial step in Luma Group's mission to transform the life sciences landscape through innovative investments.

Strategic Focus on Life Sciences

LumaBio Fund I primarily targets early-stage investments in life sciences, an area positioned for transformational advancements due to the accelerating integration of biology, chemistry, physics, and artificial intelligence. This interdisciplinary approach is expected to bring about a new generation of life sciences companies capable of redefining patient care.

Luma Group believes that scientific progress, in tandem with enhanced computational capabilities, will usher in an era of breakthrough medical solutions. "We are committed to the premise that extraordinary science, backed by patient, long-term capital, can significantly enhance millions of lives," emphasized Joshua Fink, the firm's Founder and Managing Member.

Investment Strategy

Structured as a 15-year investment vehicle, the fund aims to not only invest early in outstanding entrepreneurs but also to provide continued support through critical growth phases, from initial discovery to commercialization. The partnership with exceptional innovators is central to Luma Group’s strategy, which emphasizes long-term commitments to transformative science.

Diverse Investor Base

LumaBio Fund I has attracted a diverse array of global investors, including leading financial institutions, sovereign wealth funds, insurance companies, family offices, and ultra-high-net-worth individuals. This robust backing provides the fund with a solid foundation to pursue its ambitious growth plans.

Investment Highlights

Since its establishment in 2023, LumaBio Fund I has initiated investments in various pioneering companies poised to revolutionize medicine. Notable investments include Aeovian Pharmaceuticals, Altos Labs, Arsenal Biosciences, and others that remain undisclosed. These companies are at the forefront of scientific innovation, aiming to launch groundbreaking therapeutic solutions.

Earlier in 2026, LumaBio Fund I celebrated its first exit with the acquisition of Vaccine Company by Eli Lilly and Company, highlighting the fund's strategic approach to identifying promising scientific platforms and fostering close collaboration with management teams to achieve significant milestones.

A Vision for the Future

With experts like Themasap Khan, PhD, Co-Founder and Partner at Luma Group, predicting a decade of profound changes in medicine as scientific disciplines converge, LumaBio Fund I stands at the helm of this transformative journey. The firm’s future-oriented approach focuses on cultivating partnerships that enable visionary science to translate into practical, life-changing medical applications.

About Luma Group

Established with a mission to reshape medicine, Luma Group integrates scientific expertise, computational insights, and a proprietary AI platform into its investment strategy. The firm is dedicated to partnering with inventors and founders who are advancing significant innovations across the global life sciences arena, ensuring that their insights are matched by the necessary capital for success.

For media inquiries, please contact:
Bill Ryan
Chief Financial Officer, Luma Group
Email: [email protected]
Richie Santry
Chief of Staff, Luma Group
Email: [email protected]

This significant funding round is not just a measurement of financial success, but a milestone in the journey towards significant improvements in healthcare and well-being, representing Luma Group's commitment to catalyzing change in the life sciences industry.